Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when OPK files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsOPKO issues $125M senior secured notes at SOFR+7.5%, backed by pharma royalty streams
Filed August 14, 2026 · Period ending August 13, 2026 · ~1 min read
Key Changes
-
high
Issued $125M additional senior secured notes maturing 2044 at 3-month SOFR plus 7.5%, adding to existing notes from July 2024 agreement.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
high
Interest paid quarterly from EirGen's Pfizer profit share; if insufficient, from mazdutide royalties (Eli Lilly China sales). Debt service tied to pharma performance, not operating cash flow.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Mazdutide payments exceeding interest automatically reduce principal, but capped at $187.5M total (subject to adjustments), limiting accelerated paydown potential.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Notes secured by both royalty streams; subsidiaries OPKO Biologics and EirGen guarantee obligations and pledge assets as collateral.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR → -
medium
Agreement restricts additional debt, liens, asset sales, and material contract changes; standard default triggers include payment failures, covenant violations, and cross-defaults.
Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
Summary
OPKO Health raised $125 million through additional senior secured notes that mature in 2044, carrying a floating rate of 3-month SOFR plus 7.5% with a 4% floor—meaning the company pays at least annually. This adds to notes issued under the original July 2024 agreement, increasing the company's long-term debt burden at a relatively high cost of capital.
The financing structure is unusual: interest payments come first from royalty streams EirGen (OPKO's subsidiary) receives from a Pfizer profit-sharing arrangement, and second from mazdutide royalties tied to Eli Lilly's China sales. This means debt service depends on the commercial performance of these pharmaceutical partnerships rather than OPKO's operating cash flow.
Any mazdutide payments exceeding interest obligations automatically pay down principal, but total mazdutide contributions are capped at $187.5 million. The notes are secured by both royalty streams, and OPKO's subsidiaries have guaranteed the debt and pledged assets. Retail holders should understand this financing increases leverage while tying repayment to external pharma revenue streams. The restrictive covenants limit OPKO's financial flexibility, and the cross-default provisions mean trouble with other material debt could trigger acceleration of these notes. The high interest rate and long maturity suggest limited access to conventional financing.
Section-by-Section Diff
Event · Item 2.03 — Creation of a Direct Financial Obligation
Item 2.03 also reports this as a direct financial obligation (body incorporates the primary Item by reference).
Added in current filing · verify on EDGAR →
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The description in Item 1.01 is incorporated herein by reference.
The 8-K includes a labeled Item 2.03 section. Its body incorporates the primary Item (typically 1.01) by reference rather than restating terms — do not treat that thinness as 'Item 2.03 absent.' The company is signaling creation of a direct financial obligation alongside the agreement disclosure; keep Item 2.03 visible in the report.
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
The Notes are secured by the Royalty Payments and Mazdutide Payments paid to EirGen. The Guarantors have guaranteed the obligations under the Notes and have granted a security interest in certain assets of the Guarantors.
The notes are secured by the two royalty payment streams flowing to subsidiary EirGen. Additionally, OPKO's subsidiaries OPKO Biologics Ltd. and EirGen have guaranteed the debt and pledged certain assets as collateral, providing multiple layers of creditor protection.
Added in current filing · verify on EDGAR →
The Amended Agreement contains customary terms and covenants, including negative covenants, such as limitations on indebtedness, liens, amendments to certain material contracts and disposition of assets. The Amended Agreement also contains financial covenants, customary events of default, including defaults related to payment compliance, material inaccuracy of representations and warranties, covenant compliance, bankruptcy and insolvency proceedings, and cross-payment defaults related to certain other material indebtedness agreements.
The agreement restricts OPKO's financial flexibility through limits on additional debt, asset sales, and changes to key contracts. It includes standard default triggers for missed payments, covenant violations, bankruptcy, and defaults on other material debt, which could accelerate repayment if triggered.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Aug 17, 2026 · How we verify